Product USP’s

• Extended spectrum activity against MDR strains
• Recommended as Empirical Antibiotic treatment for Nosocomial Pneumonia with risk factor for MDR
• Pathogen as per ATS,IDSA, Harison and Goodman & Gillman.
• Very Low MIC with high susceptibility profile
• Reduced hospitalization time and treatment cost
• Cefepime plus Amikacin shows synergistic action against Gram (-) bacteria
• No resistance formulation since last 6 Years
• Better clinical & bacteriological success rates
• World wide acceptance with 8 countries patent protection
• Empirical combination enhance activity against many MDR strains of bacteria.
• Both Cefepime and Amikacin are best in class molecules